NantKwest Announces Presentation Of Preclinical Data Of HER2.taNK At The San Antonio Breast Cancer Symposium (SABCS)

CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases and NantCell, an immuno-oncology company focused on the discovery of innovative molecularly targeted therapeutics, announced today that preclinical results from the company’s HER2.taNK program will presented at the San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2015, in San Antonio, Texas.